Drugs /

cs1-car t therapy

Back to Drugs List

Overview

NCI Definition [1]:
Treatment with CAR T cells that are directed against the CS1 surface glycoprotein on multiple myeloma cells.

Clinical Trials

View Clinical Trials for cs1-car t therapy

Cs1-car t therapy has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating cs1-car t therapy, 1 is phase 1 (1 open).

SLAMF7 Expression is the most frequent biomarker inclusion criterion for cs1-car t therapy clinical trials.

Multiple myeloma is the most common disease being investigated in cs1-car t therapy clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cs1-Car T Therapy
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cs1-car t therapy and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cs1-car t-cell therapy, cs1-car t therapy, cs1-car t infusion
Drug Target(s) [2]:
SLAMF7
NCIT ID [1]:
C155800

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.